retatrutide phase 2 nejm 2023 obesity trial jastreboff of for Retatrutide for Obesity: Phase 2

For type 2 diabetes management, lower to moderate doses may still deliver therapeutic benefit without pushing patients into higher risk of GI-related side effects

Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus Fig

Patients wear compression garments for 4-6 weeks and may have drains for 1-2 weeks

NFC: Norwegian forest cat

It offers a includes coverage for Wegovy maximum savings of $100 off a one-month prescription, $200 off a two-month prescription, and $300 off a three-month prescription

The year 2026 is expected to determine how quickly these treatments move from niche adoption to broader access across the country